Skip to content
healthcare.dev

Vyvanse

NDC 59417-115, LISDEXAMFETAMINE DIMESYLATE, tablet, chewable, from Takeda Pharmaceuticals America, Inc..

Product NDC
59417-115
Status
Listed
Labeler
Takeda Pharmaceuticals America, Inc.
Dosage form
TABLET, CHEWABLE
Route
ORAL
Product type
HUMAN PRESCRIPTION DRUG
Marketing category
NDA
Application
NDA208510
DEA schedule
CII
Request
curl https://api.healthcare.dev/v1/drugs/ndc/59417-115 \
  -H "Authorization: Bearer $HDEV_API_KEY"

Product

Active ingredients and packages

Active ingredients

  • LISDEXAMFETAMINE DIMESYLATE10 mg/1

Pharmacologic classes

Central Nervous System Stimulant [EPC]; Central Nervous System Stimulation [PE]

Package NDCNDC-11Package
59417-115-0159417011501100 TABLET, CHEWABLE in 1 BOTTLE (59417-115-01)

Linked data

RxNorm, label and prices

RxNorm concepts

Related lookups

  • FDA label sections

    GET /v1/drugs/labels/704e4378-ca83-445c-8b45-3cfa51c1ecad
  • NADAC price for package 59417011501

    GET /v1/drugs/nadac/59417011501

Use it

Look up 59417-115 from code or an agent

curl
curl https://api.healthcare.dev/v1/drugs/ndc/59417-115 \
  -H "Authorization: Bearer $HDEV_API_KEY"
MCP prompt
Using the healthcare.dev MCP server, look up NDC 59417-115. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.

Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.